The aim of the LANA bio-collection is to collect samples from patients with Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) or or high-risk myelodysplastic syndrome (MDS) to facilitate access to the leukemic or myelodysplastic cells for the research teams of the National Institute of Health and Medical Research (INSERM). To do this, an additional blood or bone marrow sample to those planned in the context of patient care will be collected after signing consent. These samples will then be sent directly to the INSERM teams for immediate analysis with the aim to conduct research aimed at a better understanding of AML, ALL or MDS and improving treatments
Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment
Patient who has signed the consent form.
Patient affiliated with a social security system.
Minor patients.
Adults under guardianship.
Protected persons
Patients with high-risk AML, ALL, or MDS managed in the hematology department of the University Hospital of Nantes
Other
Prospective
Not listed
Characterization of the tumor and its microenvironment for AML, ALL or MDS in order to identify novel biomarkers or therapeutic targets
Identify genetic polymorphisms associated with an increased risk of developing AML or ALL
Click on the lead sponsor to view all of their trials.
